Trial Profile
A Randomized, Open, Parallel, Multicenter, Phase 4 Study to Evaluate the Central Aortic Pressure Effect Between Fixed Dose Combination (Duowell Tab) and Monotherapy of Telmisartan in Mild Dyslipidemia Patients With Hypertension
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 20 Aug 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin/telmisartan (Primary) ; Telmisartan
- Indications Dyslipidaemias; Hypertension
- Focus Therapeutic Use
- Sponsors Yuhan
- 12 Aug 2021 Primary endpoint (Changes from baseline in mean central systolic blood pressure) has been met.
- 12 Aug 2021 Status has been changed to discontinued.
- 12 Aug 2021 Results published in the Journal of Clinical Hypertension (Greenwich)